GRIN2A Variant in A 3-Year-Old—An Expanding Spectrum?

Neurology International

Evelina Carapancea¹  Ioana Gheța¹  Eugenia Roza¹  RalucaIoana Teleanu¹  Oana Vladacenco¹  DanielMihai Teleanu² 

[1] Department of Pediatric Neurology, “Dr Victor Gomoiu” Children’s Hospital, 22102 Bucharest, Romania;“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania;

关键词: N-methyl-D-aspartate receptor (NMDAR);    GRIN2A gene;    genetic epilepsy;    child;   

DOI  :  10.3390/neurolint13020018

来源: DOAJ

【 摘 要 】

Glutamate, the major excitatory neurotransmitter, plays a ubiquitous role in most aspects of normal brain functioning. Its indispensable position is paradoxically doubled by a high excitotoxic potential following disruption of its dynamic equilibrium. Several lines of evidence have suggested the involvement of the glutamatergic N-methyl-D-aspartate receptor (NMDAR) in learning, memory formation, and human cognition. Furthermore, NMDARs play a pivotal role in various neuropsychiatric disorders, recently being identified as an important locus for disease-associated genomic variation. The GRIN2A gene encodes the NMDAR’s GluN2A subunit. Genetic alterations of GRIN2A result in phenotypic pleiotropy, predisposing to a broad range of epilepsy syndromes, with an elusive and unpredictable evolution and response to treatment. The archetypal GRIN2A-related phenotype comprises the idiopathic focal epilepsies (IFEs), with a higher incidence of GRIN2A mutants among entities at the more severe end of the spectrum. We report the case of a patient heterozygous for GRIN2A, c.1081C>T, presenting with febrile convulsions and later superimposed atonic seizures, expressive language delay, and macrocephaly. As the number of reported GRIN2A variants is continuously increasing, the phenotypic boundaries gradually grow faint. Therefore, it is fundamental to maintain an acute critical awareness of the possible genetic etiology of different epilepsy syndromes. So far, therapeutic strategies rely on empirical observations relating genotypes to specific drugs, but the overall success of treatment remains unpredictable. Deciphering the functional consequences of individual GRIN2A variants could lead to the development of precision therapeutic approaches for patients carrying NMDAR mutations.

【 授权许可】

Unknown